Key result
Lignosulfonic acid sodium (LSAS) is a potent, selective, and allosteric inhibitor of human factor XIa with an IC50 of ~8 μg/mL, demonstrating significant anticoagulant activity in human plasma.
Why the study?
The anticoagulant activity of lignosulfonic acid sodium (LSAS), a non-saccharide heparin mimetic, was investigated.
Population
Human plasma, antithrombin-deficient plasma, factor XI-deficient plasma, and purified coagulation enzymes
Comparison
LSAS vs control or derivative conditions
Design
In vitro plasma clotting and enzyme inhibition assays
Authors
Loading...
LSAS shows in vitro FXIa inhibition; hypothesis-generating and requires in vivo validation before clinical consideration.
LSAS is a potent, selective, and allosteric inhibitor of Factor XIa, representing a promising non-saccharide heparin mimetic lead for anticoagulant development.
Kar et al. (2021) studied this question. Lignosulfonic acid sodium (LSAS) was evaluated on Factor XIa inhibition (IC50). Lignosulfonic acid sodium (LSAS) is a potent, selective, and allosteric inhibitor of human factor XIa with an IC50 of ~8 μg/mL, demonstrating significant anticoagulant activity in human plasma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: